Review





Similar Products

dss groups  (Valiant Co Ltd)
99
Valiant Co Ltd dss groups
( A ) Schedule of recombinant L. lactis- treated and <t>DSS-induced</t> colitis process. ( B ) Weight change in percent. ( C ) The changes in disease activity index (DAI), which included diarrhea, bleeding and body weight loss. ( D ) Average daily water intake per group of mice during DSS treatment. ( E ) Macroscopic appearance of the colon. ( F ) The colon length in each group. ( G ) The histopathological changes in the colon tissues were examined by H&E staining. Scale bars = 200 μm. ( H ) Histopathological scores were determined for the colon tissue samples. ( I ) Gating strategy of peripheral blood (CD45 + Ly6G + CD11b + ) in flow cytometry analysis (FACS). ( J ) The percentage of neutrophils in peripheral blood. ( K ) Gating strategy of spleen in FACS. ( L )The percentage of neutrophils in spleen. The data shown are means ± SD. Representative results from one out of two independent experiments with n = 5–6. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 versus <t>the</t> <t>pNZ-DSS</t> group; # P < 0.05, ## P < 0.01, #### P < 0.0001 versus the respective control group; ns: no significant difference. pNZ indicates pNZ8149/NZ3900 treated; <t>TsASP2</t> indicates pNZ8149/ TsASP2 /NZ3900 treated; pNZ-DSS indicates pNZ8149/NZ3900 treated and DSS induced colitis; TsASP2-DSS indicates pNZ8149/ TsASP2 /NZ3900 treated and DSS induced colitis.
Dss Groups, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cf-group/pmc12700411-150-24-39?v=Valiant+Co+Ltd
Average 99 stars, based on 1 article reviews
dss groups - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
treatment group  (Valiant Co Ltd)
98
Valiant Co Ltd treatment group
( A ) Schedule of recombinant L. lactis- treated and <t>DSS-induced</t> colitis process. ( B ) Weight change in percent. ( C ) The changes in disease activity index (DAI), which included diarrhea, bleeding and body weight loss. ( D ) Average daily water intake per group of mice during DSS treatment. ( E ) Macroscopic appearance of the colon. ( F ) The colon length in each group. ( G ) The histopathological changes in the colon tissues were examined by H&E staining. Scale bars = 200 μm. ( H ) Histopathological scores were determined for the colon tissue samples. ( I ) Gating strategy of peripheral blood (CD45 + Ly6G + CD11b + ) in flow cytometry analysis (FACS). ( J ) The percentage of neutrophils in peripheral blood. ( K ) Gating strategy of spleen in FACS. ( L )The percentage of neutrophils in spleen. The data shown are means ± SD. Representative results from one out of two independent experiments with n = 5–6. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 versus <t>the</t> <t>pNZ-DSS</t> group; # P < 0.05, ## P < 0.01, #### P < 0.0001 versus the respective control group; ns: no significant difference. pNZ indicates pNZ8149/NZ3900 treated; <t>TsASP2</t> indicates pNZ8149/ TsASP2 /NZ3900 treated; pNZ-DSS indicates pNZ8149/NZ3900 treated and DSS induced colitis; TsASP2-DSS indicates pNZ8149/ TsASP2 /NZ3900 treated and DSS induced colitis.
Treatment Group, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cf-group/pm41260570-251-6-20?v=Valiant+Co+Ltd
Average 98 stars, based on 1 article reviews
treatment group - by Bioz Stars, 2026-07
98/100 stars
  Buy from Supplier
colitis group  (Valiant Co Ltd)
98
Valiant Co Ltd colitis group
( A ) Schedule of recombinant L. lactis- treated and <t>DSS-induced</t> colitis process. ( B ) Weight change in percent. ( C ) The changes in disease activity index (DAI), which included diarrhea, bleeding and body weight loss. ( D ) Average daily water intake per group of mice during DSS treatment. ( E ) Macroscopic appearance of the colon. ( F ) The colon length in each group. ( G ) The histopathological changes in the colon tissues were examined by H&E staining. Scale bars = 200 μm. ( H ) Histopathological scores were determined for the colon tissue samples. ( I ) Gating strategy of peripheral blood (CD45 + Ly6G + CD11b + ) in flow cytometry analysis (FACS). ( J ) The percentage of neutrophils in peripheral blood. ( K ) Gating strategy of spleen in FACS. ( L )The percentage of neutrophils in spleen. The data shown are means ± SD. Representative results from one out of two independent experiments with n = 5–6. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 versus <t>the</t> <t>pNZ-DSS</t> group; # P < 0.05, ## P < 0.01, #### P < 0.0001 versus the respective control group; ns: no significant difference. pNZ indicates pNZ8149/NZ3900 treated; <t>TsASP2</t> indicates pNZ8149/ TsASP2 /NZ3900 treated; pNZ-DSS indicates pNZ8149/NZ3900 treated and DSS induced colitis; TsASP2-DSS indicates pNZ8149/ TsASP2 /NZ3900 treated and DSS induced colitis.
Colitis Group, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cf-group/pm41260431-49-6-16?v=Valiant+Co+Ltd
Average 98 stars, based on 1 article reviews
colitis group - by Bioz Stars, 2026-07
98/100 stars
  Buy from Supplier
model group  (Valiant Co Ltd)
99
Valiant Co Ltd model group
( A ) Schedule of recombinant L. lactis- treated and <t>DSS-induced</t> colitis process. ( B ) Weight change in percent. ( C ) The changes in disease activity index (DAI), which included diarrhea, bleeding and body weight loss. ( D ) Average daily water intake per group of mice during DSS treatment. ( E ) Macroscopic appearance of the colon. ( F ) The colon length in each group. ( G ) The histopathological changes in the colon tissues were examined by H&E staining. Scale bars = 200 μm. ( H ) Histopathological scores were determined for the colon tissue samples. ( I ) Gating strategy of peripheral blood (CD45 + Ly6G + CD11b + ) in flow cytometry analysis (FACS). ( J ) The percentage of neutrophils in peripheral blood. ( K ) Gating strategy of spleen in FACS. ( L )The percentage of neutrophils in spleen. The data shown are means ± SD. Representative results from one out of two independent experiments with n = 5–6. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 versus <t>the</t> <t>pNZ-DSS</t> group; # P < 0.05, ## P < 0.01, #### P < 0.0001 versus the respective control group; ns: no significant difference. pNZ indicates pNZ8149/NZ3900 treated; <t>TsASP2</t> indicates pNZ8149/ TsASP2 /NZ3900 treated; pNZ-DSS indicates pNZ8149/NZ3900 treated and DSS induced colitis; TsASP2-DSS indicates pNZ8149/ TsASP2 /NZ3900 treated and DSS induced colitis.
Model Group, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cf-group/pmc12537527-52-11-14?v=Valiant+Co+Ltd
Average 99 stars, based on 1 article reviews
model group - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
control group con  (Valiant Co Ltd)
95
Valiant Co Ltd control group con
( A ) Schedule of recombinant L. lactis- treated and <t>DSS-induced</t> colitis process. ( B ) Weight change in percent. ( C ) The changes in disease activity index (DAI), which included diarrhea, bleeding and body weight loss. ( D ) Average daily water intake per group of mice during DSS treatment. ( E ) Macroscopic appearance of the colon. ( F ) The colon length in each group. ( G ) The histopathological changes in the colon tissues were examined by H&E staining. Scale bars = 200 μm. ( H ) Histopathological scores were determined for the colon tissue samples. ( I ) Gating strategy of peripheral blood (CD45 + Ly6G + CD11b + ) in flow cytometry analysis (FACS). ( J ) The percentage of neutrophils in peripheral blood. ( K ) Gating strategy of spleen in FACS. ( L )The percentage of neutrophils in spleen. The data shown are means ± SD. Representative results from one out of two independent experiments with n = 5–6. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 versus <t>the</t> <t>pNZ-DSS</t> group; # P < 0.05, ## P < 0.01, #### P < 0.0001 versus the respective control group; ns: no significant difference. pNZ indicates pNZ8149/NZ3900 treated; <t>TsASP2</t> indicates pNZ8149/ TsASP2 /NZ3900 treated; pNZ-DSS indicates pNZ8149/NZ3900 treated and DSS induced colitis; TsASP2-DSS indicates pNZ8149/ TsASP2 /NZ3900 treated and DSS induced colitis.
Control Group Con, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cf-group/pmc12537527-52-7-14?v=Valiant+Co+Ltd
Average 95 stars, based on 1 article reviews
control group con - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
dss group  (Valiant Co Ltd)
99
Valiant Co Ltd dss group
( A ) Schedule of recombinant L. lactis- treated and <t>DSS-induced</t> colitis process. ( B ) Weight change in percent. ( C ) The changes in disease activity index (DAI), which included diarrhea, bleeding and body weight loss. ( D ) Average daily water intake per group of mice during DSS treatment. ( E ) Macroscopic appearance of the colon. ( F ) The colon length in each group. ( G ) The histopathological changes in the colon tissues were examined by H&E staining. Scale bars = 200 μm. ( H ) Histopathological scores were determined for the colon tissue samples. ( I ) Gating strategy of peripheral blood (CD45 + Ly6G + CD11b + ) in flow cytometry analysis (FACS). ( J ) The percentage of neutrophils in peripheral blood. ( K ) Gating strategy of spleen in FACS. ( L )The percentage of neutrophils in spleen. The data shown are means ± SD. Representative results from one out of two independent experiments with n = 5–6. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 versus <t>the</t> <t>pNZ-DSS</t> group; # P < 0.05, ## P < 0.01, #### P < 0.0001 versus the respective control group; ns: no significant difference. pNZ indicates pNZ8149/NZ3900 treated; <t>TsASP2</t> indicates pNZ8149/ TsASP2 /NZ3900 treated; pNZ-DSS indicates pNZ8149/NZ3900 treated and DSS induced colitis; TsASP2-DSS indicates pNZ8149/ TsASP2 /NZ3900 treated and DSS induced colitis.
Dss Group, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cf-group/pm40987980-150-24-32?v=Valiant+Co+Ltd
Average 99 stars, based on 1 article reviews
dss group - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
cf-forest user groups 1.0  (Ambio Inc)
90
Ambio Inc cf-forest user groups 1.0
( A ) Schedule of recombinant L. lactis- treated and <t>DSS-induced</t> colitis process. ( B ) Weight change in percent. ( C ) The changes in disease activity index (DAI), which included diarrhea, bleeding and body weight loss. ( D ) Average daily water intake per group of mice during DSS treatment. ( E ) Macroscopic appearance of the colon. ( F ) The colon length in each group. ( G ) The histopathological changes in the colon tissues were examined by H&E staining. Scale bars = 200 μm. ( H ) Histopathological scores were determined for the colon tissue samples. ( I ) Gating strategy of peripheral blood (CD45 + Ly6G + CD11b + ) in flow cytometry analysis (FACS). ( J ) The percentage of neutrophils in peripheral blood. ( K ) Gating strategy of spleen in FACS. ( L )The percentage of neutrophils in spleen. The data shown are means ± SD. Representative results from one out of two independent experiments with n = 5–6. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 versus <t>the</t> <t>pNZ-DSS</t> group; # P < 0.05, ## P < 0.01, #### P < 0.0001 versus the respective control group; ns: no significant difference. pNZ indicates pNZ8149/NZ3900 treated; <t>TsASP2</t> indicates pNZ8149/ TsASP2 /NZ3900 treated; pNZ-DSS indicates pNZ8149/NZ3900 treated and DSS induced colitis; TsASP2-DSS indicates pNZ8149/ TsASP2 /NZ3900 treated and DSS induced colitis.
Cf Forest User Groups 1.0, supplied by Ambio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cf-group/pmc10087706__COBI___37___0___s001-312-12-31?v=Ambio+Inc
Average 90 stars, based on 1 article reviews
cf-forest user groups 1.0 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


( A ) Schedule of recombinant L. lactis- treated and DSS-induced colitis process. ( B ) Weight change in percent. ( C ) The changes in disease activity index (DAI), which included diarrhea, bleeding and body weight loss. ( D ) Average daily water intake per group of mice during DSS treatment. ( E ) Macroscopic appearance of the colon. ( F ) The colon length in each group. ( G ) The histopathological changes in the colon tissues were examined by H&E staining. Scale bars = 200 μm. ( H ) Histopathological scores were determined for the colon tissue samples. ( I ) Gating strategy of peripheral blood (CD45 + Ly6G + CD11b + ) in flow cytometry analysis (FACS). ( J ) The percentage of neutrophils in peripheral blood. ( K ) Gating strategy of spleen in FACS. ( L )The percentage of neutrophils in spleen. The data shown are means ± SD. Representative results from one out of two independent experiments with n = 5–6. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 versus the pNZ-DSS group; # P < 0.05, ## P < 0.01, #### P < 0.0001 versus the respective control group; ns: no significant difference. pNZ indicates pNZ8149/NZ3900 treated; TsASP2 indicates pNZ8149/ TsASP2 /NZ3900 treated; pNZ-DSS indicates pNZ8149/NZ3900 treated and DSS induced colitis; TsASP2-DSS indicates pNZ8149/ TsASP2 /NZ3900 treated and DSS induced colitis.

Journal: PLOS Neglected Tropical Diseases

Article Title: Aspartic protease 2 from Trichinella spiralis excretion/secretion products hydrolyzes tight junctions of intestinal epithelial cells

doi: 10.1371/journal.pntd.0013805

Figure Lengend Snippet: ( A ) Schedule of recombinant L. lactis- treated and DSS-induced colitis process. ( B ) Weight change in percent. ( C ) The changes in disease activity index (DAI), which included diarrhea, bleeding and body weight loss. ( D ) Average daily water intake per group of mice during DSS treatment. ( E ) Macroscopic appearance of the colon. ( F ) The colon length in each group. ( G ) The histopathological changes in the colon tissues were examined by H&E staining. Scale bars = 200 μm. ( H ) Histopathological scores were determined for the colon tissue samples. ( I ) Gating strategy of peripheral blood (CD45 + Ly6G + CD11b + ) in flow cytometry analysis (FACS). ( J ) The percentage of neutrophils in peripheral blood. ( K ) Gating strategy of spleen in FACS. ( L )The percentage of neutrophils in spleen. The data shown are means ± SD. Representative results from one out of two independent experiments with n = 5–6. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 versus the pNZ-DSS group; # P < 0.05, ## P < 0.01, #### P < 0.0001 versus the respective control group; ns: no significant difference. pNZ indicates pNZ8149/NZ3900 treated; TsASP2 indicates pNZ8149/ TsASP2 /NZ3900 treated; pNZ-DSS indicates pNZ8149/NZ3900 treated and DSS induced colitis; TsASP2-DSS indicates pNZ8149/ TsASP2 /NZ3900 treated and DSS induced colitis.

Article Snippet: Mice in the control groups (pNZ and TsASP2 groups) received autoclaved water for the entire 10-day period, while experimental colitis was induced in the DSS groups (pNZ-DSS and TsASP2-DSS groups) by administering a 2.5% (wt/vol) dextran sulfate sodium (DSS, MP Biomedicals, MW 36,000–50,000) solution as drinking water for the first 7 days, followed by autoclaved water for the subsequent 3 days.

Techniques: Recombinant, Activity Assay, Staining, Flow Cytometry, Control